Study of SHR-8068 Combined With Adebrelimab and Platinum-containing Chemotherapy in the Treatment of Advanced Gastric and Esophageal Cancer

Prior treatment

• Untreated (radiation or surgery) central nervous system metastasis, or accompanied by meningeal metastasis, spinal cord compression, etc.;
• Previous or co-existing malignant neoplasms;
• People who have previously received an organ transplant;
• Known allergic reactions to adebrelimab or other monoclonal antibodies or investigational drugs;

Other illness

• The presence of any active or known autoimmune disease;
• Have clinical symptoms or diseases of the heart that are not well controlled;

Other

• Her2-positive patients;
• Uncontrolled pleural effusion, pericardial effusion, or peritoneal effusion with clinical symptoms;

• Volunteer to join the clinical study, and sign the informed consent, compliance is good, can cooperate with follow-up;
• Aged 18-75 at the time of signing the informed consent;
• Histologically or cytologically confirmed, unresectable, advanced or recurrent/metastatic adenocarcinoma of the gastric or gastroesophageal junction, or unresectable or recurrent/metastatic esophageal squamous cell carcinoma without radical chemoradiation;
• At least one measurable lesion consistent with RECIST v1.1;
• ECOG PS score: 0-1;
• The organ function level is good;